- Home
- LDTC vs KPTI Comparison
LDTC vs KPTI Comparison
Compare LDTC & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- KPTI
- Stock Information
- Founded
- LDTC 2007
- KPTI 2008
- Country
- LDTC Canada
- KPTI United States
- Employees
- LDTC N/A
- KPTI N/A
- Industry
- LDTC Blank Checks
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- KPTI Health Care
- Exchange
- LDTC Nasdaq
- KPTI Nasdaq
- Market Cap
- LDTC 37.5M
- KPTI 33.6M
- IPO Year
- LDTC N/A
- KPTI 2013
- Fundamental
- Price
- LDTC $0.43
- KPTI $5.62
- Analyst Decision
- LDTC Buy
- KPTI Strong Buy
- Analyst Count
- LDTC 2
- KPTI 5
- Target Price
- LDTC $3.00
- KPTI $61.00
- AVG Volume (30 Days)
- LDTC 170.7K
- KPTI 135.2K
- Earning Date
- LDTC 05-13-2025
- KPTI 05-07-2025
- Dividend Yield
- LDTC N/A
- KPTI N/A
- EPS Growth
- LDTC N/A
- KPTI N/A
- EPS
- LDTC N/A
- KPTI N/A
- Revenue
- LDTC $331,997.00
- KPTI $145,237,000.00
- Revenue This Year
- LDTC $906.25
- KPTI $4.87
- Revenue Next Year
- LDTC $149.88
- KPTI $16.29
- P/E Ratio
- LDTC N/A
- KPTI N/A
- Revenue Growth
- LDTC 141.86
- KPTI N/A
- 52 Week Low
- LDTC $0.22
- KPTI $3.51
- 52 Week High
- LDTC $2.75
- KPTI $18.00
- Technical
- Relative Strength Index (RSI)
- LDTC 46.01
- KPTI 53.53
- Support Level
- LDTC $0.36
- KPTI $3.83
- Resistance Level
- LDTC $0.42
- KPTI $6.56
- Average True Range (ATR)
- LDTC 0.07
- KPTI 0.48
- MACD
- LDTC 0.01
- KPTI 0.34
- Stochastic Oscillator
- LDTC 37.34
- KPTI 68.67
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation. The company generates the majority of its revenue from France, Canada, and the United states.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.